SEC Form 4 · accession 0001808343-26-000010
Immunome Inc. · IMNM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Isaac Barchas
Director
Period of report
Aug 10, 2026
Accepted (ET)
Aug 12, 2026 · 5:47 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001472012
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Aug 10, 2026 | S | 10,125 | $26.07 | D | 62,291 | I | See footnote |
| Common StockF4,F3 | Aug 11, 2026 | S | 62,291 | $26.23 | D | 0 | I | See footnote |
| Common Stock | Aug 12, 2026 | S | 11,048 | $27.25 | D | 92,211 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC ("ABHMC") on March 31, 2026.
- F2The weighted average sale price for the transaction report was $26.07, and the range of prices were between $26.005 and $26.14, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F3ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
- F4The weighted average sale price for the transaction report was $26.23, and the range of prices were between $26.00 and $26.48, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F5The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2026.